SLK-Kliniken Heilbronn GmbH

Hospital


Location: Heilbronn, Germany (DE) DE

ISNI: 0000000101427696

ROR: https://ror.org/05btveq09

Show on Map:


close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Epidemiology of patch tested patients with permanent tattoos—A comparative analysis of 9693 IVDK patients (2020–2022) (2024) Schubert S, Oppel E, Bauer A, Schröder-Kraft C, Löffler H, Strom K, Worm M, et al. Journal article Ten recommendations for sarcoma surgery: consensus of the surgical societies based on the German S3 guideline “Adult Soft Tissue Sarcomas” (2023) Jakob J, Andreou D, Bedke J, Denschlag D, Dürr HR, Frese S, Gösling T, et al. Journal article Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREG (2023) Zaremba A, Mohr P, Gutzmer R, Meier F, Pföhler C, Weichenthal M, Terheyden P, et al. Journal article ETOPOSIDE FOR PRIMARY HLH - BETTER THAN ITS REPUTATION (2023) Lehmberg K, Ledig S, Wustrau K, Kontny U, Westphal S, Hundsdoerfer P, Jorch N, et al. Conference contribution Systematic symptom screening in patients with advanced cancer treated in certified oncology centers: results of the prospective multicenter German KeSBa project (2023) Braulke F, Para S, Alt-Epping B, Tewes M, Bäumer M, Haberland B, Mayer-Steinacker R, et al. Journal article Sequential treatment patterns over time for advanced renal cell carcinoma: data from the German research platform CARAT (2022) Goebell P, Gruellich C, Mueller L, Boegemann M, Martens U, Von Der Heyde E, Reichert D, et al. Conference contribution Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial (2022) González-Martín A, Desauw C, Heitz F, Cropet C, Gargiulo P, Berger R, Ochi H, et al. Journal article Development of brain metastases and survival outcomes upon first-line systemic therapy in BRAF mutant and BRAF wildtype melanoma patients: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG (2022) Franklin C, Mohr P, Meier F, Weichenthal M, Grimmel-Mann I, Gutzmer R, Utikal JS, et al. Conference contribution Genetic modifiers of fetal hemoglobin affect the course of sickle cell disease in patients treated with hydroxyurea (2022) Allard P, Alhaj N, Lobitz S, Cario H, Jarisch A, Grosse R, Oevermann L, et al. Journal article Lessons learned after one year of COVID-19 from a urologist and radiotherapist view: A German survey on prostate cancer diagnosis and treatment (2022) Harke NN, Wagner C, Hermann RM, Hadaschik BA, Radtke JP, Altay-Langguth A, Aufderklamm S, et al. Journal article
1 2 3 4